Polycystic ovary syndrome, a disorder characterized by irregular menses, hormonal alteration and the appearance of multiple cysts in the ovaries, affects approximately 8% of the female population. What causes this pathology is still a doubt and the diagnosis and treatment has been much discussed. What is known is that this is one of the main reasons for infertility in women, to which you can add some metabolic disorders, such as obesity or insulin resistance.
A study conducted by a group of researchers from different American universities, in order to ratify the results of small studies on the best method to treat infertility in women with polycystic ovarian syndrome, and which has been published in The New England Journal of Medicine, defines that the ancient medication used to induce ovulation through its action on follicle stimulating hormone, Clomiphene citrate is the best option for women who suffer from this disorder to become pregnantIt is also the simplest, cheapest, safest and most effective treatment.
Of more recent use was metformin, a medicine used to treat type 2 diabetes, which by improving glucose and obesity favored conception. The study was carried out with 626 infertile women for this syndrome and distributed them in three groups, one group received the antidiabetic drug (extended release metformin), another the ovulation inducer (clomiphene citrate) and the third received a combination of both medications. The treatment and follow-up lasted a maximum of 30 weeks or until they achieved pregnancy.
At the end of the study, women who had received clomiphene showed a birth rate three times higher than those of the metformin group, in addition, the former also had a greater number of multiple pregnancies.
Those who took a combination of both drugs showed an ovulation rate higher than the rest, but births were not fulfilled, although they matched multiple pregnancies with the group that received the ovulation inducer.
Previous studies had suggested the opposite of this, but the result was not analyzed at birth, but in the ovulation rate, which is not the desire of women suffering from this disorder.
